Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036601752> ?p ?o ?g. }
- W3036601752 endingPage "459" @default.
- W3036601752 startingPage "445" @default.
- W3036601752 abstract "•The metabolic status of eicosanoids changed when AMI occurred. PGJ2, PGI2, 5-HETE, LTB4 and PGF2α would be key targets. •2 g daily of ω-3 PUFA reduced TG, Apo B and Lp(a) levels in patients with AMI, meanwhile increased NO production. •ω-3 PUFA partially shifted the eicosanoid profile. PGJ2 and LTB4 continuously decreased, while EEQs and EDPs increased. •TG, Apo B and Lp(a) was negatively correlated with DHA and EEQs, NO was positively correlated with DHA, EEQs and PGJ2. Background & aims Omega-3 polyunsaturated fatty acid (ω-3 PUFA) have been reported to have beneficial cardiovascular effects, but its mechanism of protection against acute myocardial infarction (AMI) who are under guideline-based therapy is not fully understood. Here, we used a metabolomic approach to systematically analyze the eicosanoid metabolites induced by ω-3 PUFA supplementation and investigated the underlying mechanisms. Methods Participants with AMI after successful percutaneous coronary intervention were randomized to 3 months of 2 g daily ω-3 PUFA and guideline-adjusted therapy (n = 30, ω-3 therapy) or guideline-adjusted therapy alone (n = 30, Usual therapy). Functional PUFA-derived eicosanoids in plasma were profiled by metabolomics. Clinical and laboratory tests were obtained before and 3 months after baseline and after the study therapy. Results By intent-to-treat analysis, the content of 11-HDoHE, 20-HDoHE and 16,17-EDP and that of epoxyeicosatetraenoic acids (EEQs), derived from docosahexaenoic acid and eicosapentaenoic acid, respectively, were significantly higher with ω-3 group than Usual therapy, whereas that of prostaglandin J2 (PGJ2) and leukotriene B4, derived from arachidonic acid, was significantly decreased. As compared with Usual therapy, ω-3 PUFA therapy significantly reduced levels of triglycerides (−6.3%, P < 0.05), apolipoprotein B (−4.9%, P < 0.05) and lipoprotein(a) (−37.0%, P < 0.05) and increased nitric oxide level (62.2%, P < 0.05). In addition, the levels of these variables were positively correlated with change in 16,17-EDP and EEQs content but negatively with change in PGJ2 content. Conclusions ω-3 PUFA supplementation may improve lipid metabolism and endothelial function possibly by affecting eicosanoid metabolic status at a systemic level during convalescent healing after AMI. Clinical trial registration URL: http://www.chictr.org.cn. Unique identifier: ChiCTR1900025859. Omega-3 polyunsaturated fatty acid (ω-3 PUFA) have been reported to have beneficial cardiovascular effects, but its mechanism of protection against acute myocardial infarction (AMI) who are under guideline-based therapy is not fully understood. Here, we used a metabolomic approach to systematically analyze the eicosanoid metabolites induced by ω-3 PUFA supplementation and investigated the underlying mechanisms. Participants with AMI after successful percutaneous coronary intervention were randomized to 3 months of 2 g daily ω-3 PUFA and guideline-adjusted therapy (n = 30, ω-3 therapy) or guideline-adjusted therapy alone (n = 30, Usual therapy). Functional PUFA-derived eicosanoids in plasma were profiled by metabolomics. Clinical and laboratory tests were obtained before and 3 months after baseline and after the study therapy. By intent-to-treat analysis, the content of 11-HDoHE, 20-HDoHE and 16,17-EDP and that of epoxyeicosatetraenoic acids (EEQs), derived from docosahexaenoic acid and eicosapentaenoic acid, respectively, were significantly higher with ω-3 group than Usual therapy, whereas that of prostaglandin J2 (PGJ2) and leukotriene B4, derived from arachidonic acid, was significantly decreased. As compared with Usual therapy, ω-3 PUFA therapy significantly reduced levels of triglycerides (−6.3%, P < 0.05), apolipoprotein B (−4.9%, P < 0.05) and lipoprotein(a) (−37.0%, P < 0.05) and increased nitric oxide level (62.2%, P < 0.05). In addition, the levels of these variables were positively correlated with change in 16,17-EDP and EEQs content but negatively with change in PGJ2 content. ω-3 PUFA supplementation may improve lipid metabolism and endothelial function possibly by affecting eicosanoid metabolic status at a systemic level during convalescent healing after AMI." @default.
- W3036601752 created "2020-06-25" @default.
- W3036601752 creator A5000875903 @default.
- W3036601752 creator A5010776860 @default.
- W3036601752 creator A5026278105 @default.
- W3036601752 creator A5046775442 @default.
- W3036601752 creator A5054566233 @default.
- W3036601752 creator A5062607187 @default.
- W3036601752 creator A5065542261 @default.
- W3036601752 creator A5084655226 @default.
- W3036601752 creator A5089211939 @default.
- W3036601752 date "2021-02-01" @default.
- W3036601752 modified "2023-10-14" @default.
- W3036601752 title "Omega-3 polyunsaturated fatty acid supplementation improves lipid metabolism and endothelial function by providing a beneficial eicosanoid-pattern in patients with acute myocardial infarction: A randomized, controlled trial" @default.
- W3036601752 cites W1555489744 @default.
- W3036601752 cites W1913730804 @default.
- W3036601752 cites W1974316867 @default.
- W3036601752 cites W1980358798 @default.
- W3036601752 cites W1990695275 @default.
- W3036601752 cites W1990721651 @default.
- W3036601752 cites W1996641618 @default.
- W3036601752 cites W2012655434 @default.
- W3036601752 cites W2020904085 @default.
- W3036601752 cites W2026310866 @default.
- W3036601752 cites W2039846024 @default.
- W3036601752 cites W2045096300 @default.
- W3036601752 cites W2050040190 @default.
- W3036601752 cites W2071755201 @default.
- W3036601752 cites W2093639021 @default.
- W3036601752 cites W2097692576 @default.
- W3036601752 cites W2099767767 @default.
- W3036601752 cites W2099814455 @default.
- W3036601752 cites W2100419832 @default.
- W3036601752 cites W2105206504 @default.
- W3036601752 cites W2105953302 @default.
- W3036601752 cites W2113302343 @default.
- W3036601752 cites W2129935236 @default.
- W3036601752 cites W2139086060 @default.
- W3036601752 cites W2142347023 @default.
- W3036601752 cites W2144181696 @default.
- W3036601752 cites W2144663588 @default.
- W3036601752 cites W2146228563 @default.
- W3036601752 cites W2153683688 @default.
- W3036601752 cites W2164337212 @default.
- W3036601752 cites W2247997571 @default.
- W3036601752 cites W2292502644 @default.
- W3036601752 cites W2313992909 @default.
- W3036601752 cites W2516190779 @default.
- W3036601752 cites W2526556731 @default.
- W3036601752 cites W2729728820 @default.
- W3036601752 cites W2743332573 @default.
- W3036601752 cites W2744977423 @default.
- W3036601752 cites W2768051700 @default.
- W3036601752 cites W2891229106 @default.
- W3036601752 cites W2892073816 @default.
- W3036601752 cites W2899669642 @default.
- W3036601752 cites W2910235399 @default.
- W3036601752 cites W2915142973 @default.
- W3036601752 cites W594491768 @default.
- W3036601752 doi "https://doi.org/10.1016/j.clnu.2020.05.034" @default.
- W3036601752 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33041091" @default.
- W3036601752 hasPublicationYear "2021" @default.
- W3036601752 type Work @default.
- W3036601752 sameAs 3036601752 @default.
- W3036601752 citedByCount "5" @default.
- W3036601752 countsByYear W30366017522021 @default.
- W3036601752 countsByYear W30366017522022 @default.
- W3036601752 countsByYear W30366017522023 @default.
- W3036601752 crossrefType "journal-article" @default.
- W3036601752 hasAuthorship W3036601752A5000875903 @default.
- W3036601752 hasAuthorship W3036601752A5010776860 @default.
- W3036601752 hasAuthorship W3036601752A5026278105 @default.
- W3036601752 hasAuthorship W3036601752A5046775442 @default.
- W3036601752 hasAuthorship W3036601752A5054566233 @default.
- W3036601752 hasAuthorship W3036601752A5062607187 @default.
- W3036601752 hasAuthorship W3036601752A5065542261 @default.
- W3036601752 hasAuthorship W3036601752A5084655226 @default.
- W3036601752 hasAuthorship W3036601752A5089211939 @default.
- W3036601752 hasConcept C126322002 @default.
- W3036601752 hasConcept C134018914 @default.
- W3036601752 hasConcept C168563851 @default.
- W3036601752 hasConcept C181199279 @default.
- W3036601752 hasConcept C19038510 @default.
- W3036601752 hasConcept C2776091944 @default.
- W3036601752 hasConcept C2776352991 @default.
- W3036601752 hasConcept C2777171753 @default.
- W3036601752 hasConcept C2778078955 @default.
- W3036601752 hasConcept C2908562933 @default.
- W3036601752 hasConcept C500558357 @default.
- W3036601752 hasConcept C543025807 @default.
- W3036601752 hasConcept C55493867 @default.
- W3036601752 hasConcept C71924100 @default.
- W3036601752 hasConcept C86803240 @default.
- W3036601752 hasConcept C90924648 @default.
- W3036601752 hasConcept C98274493 @default.
- W3036601752 hasConceptScore W3036601752C126322002 @default.
- W3036601752 hasConceptScore W3036601752C134018914 @default.
- W3036601752 hasConceptScore W3036601752C168563851 @default.